MMP-13 promoter polymorphisms in patients with chronic periodontitis: effects on GCF MMP-13 levels and outcome of periodontal therapy.
OBJECTIVE
The aims of this study were to investigate (a) the matrix metalloproteinase-13 (MMP-13) promoter polymorphisms in severe, generalized chronic periodontitis (CP), (b) the relationship of periodontal therapy outcome with these genotypes and (c) gingival crevicular fluid (GCF) MMP-13 level-MMP-13 genotype correlation.


METHODS
Genomic DNA was obtained from peripheral blood of 102 patients with severe, generalized CP, and 98 periodontally healthy subjects. MMP-13 -77A/G and 11A/12A polymorphisms were determined by the polymerase chain reaction-restriction fragment length polymorphism and DNA sequencing methods, respectively. Fifty-eight CP patients received non-surgical periodontal therapy and were followed for 6 months. Clinical periodontal parameters and GCF samples were collected at baseline and at 6 months. GCF MMP-13 levels were analysed by an enzyme-linked immunosorbent assay.


RESULTS
The distribution of MMP-13 -77AG genotypes and allele frequencies did not differ significantly between study groups (p>0.05). Study subjects, except 3, had the 11A/11A genotype. MMP-13 -77G allele carriers had similar GCF MMP-13 levels and clinical periodontal parameters compared with AA genotypes after non-surgical periodontal therapy (p<0.05).


CONCLUSIONS
These data suggest that the -77A/G and 11A/12A polymorphisms of MMP-13 gene are not associated with susceptibility to severe, generalized CP in a Turkish population. It seems that -77G allele carriage may not influence the outcome of periodontal therapy.
Pirhan
Demet
D
Department of Periodontology, School of Dentistry, Ege University, Izmir, Turkey.
Atilla
Gül
G
Emingil
Gülnur
G
Tervahartiala
Taina
T
Sorsa
Timo
T
Berdeli
Afig
A
D000225:Adenine; D000328:Adult; D000368:Aged; D016301:Alveolar Bone Loss / Q000201:enzymology / Q000628:therapy; D055113:Chronic Periodontitis / Q000201:enzymology* / Q000235:genetics / Q000628:therapy; D004247:DNA / Q000032:analysis; D012534:Dental Scaling; D005260:Female; D005500:Follow-Up Studies; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease / Q000235:genetics; D005838:Genotype; D005883:Gingival Crevicular Fluid / Q000201:enzymology*; D005884:Gingival Hemorrhage / Q000201:enzymology / Q000628:therapy; D006147:Guanine; D006801:Humans; D054643:INDEL Mutation / Q000235:genetics; D008297:Male; D053509:Matrix Metalloproteinase 13 / Q000235:genetics*; D008875:Middle Aged; D017622:Periodontal Attachment Loss / Q000201:enzymology / Q000628:therapy; D011110:Polymorphism, Genetic / Q000235:genetics*; D011401:Promoter Regions, Genetic / Q000235:genetics*; D016745:Root Planing; D017422:Sequence Analysis, DNA; D016896:Treatment Outcome
D006147:Guanine; D004247:DNA; D053509:Matrix Metalloproteinase 13; D000225:Adenine